Dermata Therapeutics Warrant Stock Analysis
| DRMAW Stock | USD 0.02 0.01 38.27% |
Dermata Therapeutics Warrant is fairly valued with Real Value of 0.0165 and Hype Value of 0.0176. The main objective of Dermata Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dermata Therapeutics Warrant is worth, separate from its market price. There are two main types of Dermata Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dermata Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Dermata Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Dermata Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Dermata Stock Analysis Notes
The company recorded a loss per share of 2.16. Dermata Therapeutics had not issued any dividends in recent years. To learn more about Dermata Therapeutics Warrant call the company at 858 800 2543 or check out https://www.dermatarx.com.Dermata Therapeutics Investment Alerts
| Dermata Therapeutics is way too risky over 90 days horizon | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics appears to be risky and price may revert if volatility continues | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures |
Technical Drivers
As of the 17th of November 2025, Dermata Therapeutics shows the Mean Deviation of 10.71, coefficient of variation of 1499.78, and Downside Deviation of 15.45. Dermata Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Dermata Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Dermata Therapeutics is priced favorably, providing market reflects its regular price of 0.0171 per share. As Dermata Therapeutics appears to be a penny stock we also advise to verify its total risk alpha numbers.Dermata Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Dermata Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Dermata Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Hoose Kyri K. over three weeks ago Acquisition by Van Hoose Kyri K. of 78741 shares of Dermata Therapeutics subject to Rule 16b-3 | ||
Mento Steven J over three months ago Acquisition by Mento Steven J of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
David Hale over a year ago Acquisition by David Hale of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Fisher Mary over a year ago Acquisition by Fisher Mary of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Sandler Andrew Seth over a year ago Acquisition by Sandler Andrew Seth of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Bedoya-toro Munera Maria E over a year ago Acquisition by Bedoya-toro Munera Maria E of 15000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 |
Dermata Therapeutics Predictive Daily Indicators
Dermata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dermata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.11 | |||
| Daily Balance Of Power | (5.05) | |||
| Rate Of Daily Change | 0.62 | |||
| Day Median Price | 0.0181 | |||
| Day Typical Price | 0.0177 | |||
| Market Facilitation Index | 0.0021 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
Dermata Therapeutics Forecast Models
Dermata Therapeutics' time-series forecasting models are one of many Dermata Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dermata Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Dermata Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.